Drug Profile
Research programme: transplant rejection targets - Novartis/Rigel
Latest Information Update: 17 Nov 2005
Price :
$50
*
At a glance
- Originator Novartis; Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 17 Nov 2005 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
- 30 Nov 2002 The research phase of this programme has been terminated
- 26 May 1999 Preclinical development for Transplant rejection in USA (Unknown route)